Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death

Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality. The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86-0.96; P < .01). The patients with a...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget 2016-07, Vol.7 (27), p.42208-42215
Main Authors: Huang, Wen-Yen, Li, Chia-Hsiang, Lin, Cheng-Li, Liang, Ji-An
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Case-Control Studies
Dyslipidemias - complications
Dyslipidemias - drug therapy
Dyslipidemias - mortality
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Incidence
Lung Neoplasms - complications
Lung Neoplasms - mortality
Male
Middle Aged
Proportional Hazards Models
Prospective Studies
Research Paper
Risk Factors
Taiwan
Time Factors
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical studies have obtained inconsistent results of statin use on cancer outcomes. This study investigated the association between statin use and lung cancer mortality. The use of statin decreased mortality (hazard ratio = 0.91; 95% confidence interval: 0.86-0.96; P < .01). The patients with a high cumulative defined daily dose of statin use before lung cancer diagnosis exhibited a low risk of mortality. We conducted a population-based case-control study of patients with dyslipidemia. Among them, 6270 had used statins for at least 3 months before lung cancer diagnosis, and 6270 had never used statins. We found that statin use can reduce lung cancer mortality. A further prospective study is necessary to confirm these findings.
ISSN:1949-2553
1949-2553
DOI:10.18632/oncotarget.9906